CN109451744B - 用于危重患者的死亡预后的生物标志物 - Google Patents

用于危重患者的死亡预后的生物标志物 Download PDF

Info

Publication number
CN109451744B
CN109451744B CN201780039163.2A CN201780039163A CN109451744B CN 109451744 B CN109451744 B CN 109451744B CN 201780039163 A CN201780039163 A CN 201780039163A CN 109451744 B CN109451744 B CN 109451744B
Authority
CN
China
Prior art keywords
patient
polynucleotide
death
biomarker
sepsis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780039163.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN109451744A (zh
Inventor
普尔威施·卡特里
蒂莫西·E·斯威尼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Priority to CN202210792075.2A priority Critical patent/CN115161389A/zh
Publication of CN109451744A publication Critical patent/CN109451744A/zh
Application granted granted Critical
Publication of CN109451744B publication Critical patent/CN109451744B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
    • C40B40/08—Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/20—Polymerase chain reaction [PCR]; Primer or probe design; Probe optimisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2537/00—Reactions characterised by the reaction format or use of a specific feature
    • C12Q2537/10—Reactions characterised by the reaction format or use of a specific feature the purpose or use of
    • C12Q2537/165—Mathematical modelling, e.g. logarithm, ratio
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/20—Dermatological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/26—Infectious diseases, e.g. generalised sepsis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medical Informatics (AREA)
  • Theoretical Computer Science (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Evolutionary Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
CN201780039163.2A 2016-06-26 2017-04-25 用于危重患者的死亡预后的生物标志物 Active CN109451744B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210792075.2A CN115161389A (zh) 2016-06-26 2017-04-25 用于危重患者的死亡预后的生物标志物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662354789P 2016-06-26 2016-06-26
US62/354,789 2016-06-26
PCT/US2017/029468 WO2018004806A1 (en) 2016-06-26 2017-04-25 Biomarkers for use in prognosis of mortality in critically ill patients

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202210792075.2A Division CN115161389A (zh) 2016-06-26 2017-04-25 用于危重患者的死亡预后的生物标志物

Publications (2)

Publication Number Publication Date
CN109451744A CN109451744A (zh) 2019-03-08
CN109451744B true CN109451744B (zh) 2022-08-05

Family

ID=60786346

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201780039163.2A Active CN109451744B (zh) 2016-06-26 2017-04-25 用于危重患者的死亡预后的生物标志物
CN202210792075.2A Pending CN115161389A (zh) 2016-06-26 2017-04-25 用于危重患者的死亡预后的生物标志物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202210792075.2A Pending CN115161389A (zh) 2016-06-26 2017-04-25 用于危重患者的死亡预后的生物标志物

Country Status (7)

Country Link
US (4) US10344332B2 (enExample)
EP (1) EP3475473A4 (enExample)
JP (2) JP2019530878A (enExample)
CN (2) CN109451744B (enExample)
AU (2) AU2017289600A1 (enExample)
CA (1) CA3024724A1 (enExample)
WO (1) WO2018004806A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109451744B (zh) * 2016-06-26 2022-08-05 斯坦福大学托管董事会 用于危重患者的死亡预后的生物标志物
WO2018140256A1 (en) * 2017-01-17 2018-08-02 Duke University Gene expression signatures useful to predict or diagnose sepsis and methods of using the same
EP3759235B1 (en) * 2018-02-27 2025-02-19 The Board Of Trustees Of The Leland Stanford Junior University Classifier for identification of robust sepsis subtypes
CA3133639A1 (en) * 2019-03-22 2020-10-01 Inflammatix, Inc. Systems and methods for deriving and optimizing classifiers from multiple datasets
JP2022530323A (ja) * 2019-04-28 2022-06-29 ビスビュー メディカル，インコーポレイテッド デジタル検出能力および無線接続性を有する分子診断デバイス
BR112022008068A2 (pt) * 2019-10-28 2022-07-12 Hoffmann La Roche Métodos para auxiliar na avaliação de risco de um paciente com suspeita de sepse e método implementado por computador para a avaliação de um paciente com suspeita de sepse
JP2023525489A (ja) * 2020-04-29 2023-06-16 インフラマティックス インコーポレイテッド ウイルス感染症を有する対象の死亡率リスクの決定
WO2022066963A1 (en) * 2020-09-25 2022-03-31 The Board Of Trustees Of The Leland Stanford Junior University Method for determining a virally-infected subject's risk of developing severe symptoms
CN114606308A (zh) * 2022-01-26 2022-06-10 江门市中心医院 脓毒症ards的预后与治疗标志物

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1738908A (zh) * 2002-11-12 2006-02-22 贝克顿迪金森公司 使用生物标记谱诊断脓毒或者sirs
CN101208602A (zh) * 2005-04-15 2008-06-25 贝克顿迪金森公司 脓毒症的诊断
CN103492590A (zh) * 2011-02-22 2014-01-01 卡里斯生命科学卢森堡控股有限责任公司 循环生物标志物
WO2015135071A1 (en) * 2014-03-14 2015-09-17 Hancock Robert E W Diagnostic for sepsis
CN105518153A (zh) * 2013-06-20 2016-04-20 因姆内克斯普雷斯私人有限公司 生物标志物鉴定

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5245615A (en) 1991-06-06 1993-09-14 International Business Machines Corporation Diagnostic system and interface for a personal computer
NZ333718A (en) 1996-07-12 2000-10-27 First Opinion Corp Computerized medical diagnostic system utilizing list-based processing
US20050196817A1 (en) 2004-01-20 2005-09-08 Molecular Staging Inc. Biomarkers for sepsis
DE102005050933A1 (de) * 2005-10-21 2007-04-26 Justus-Liebig-Universität Giessen Erfindung betreffend Expressionsprofile zur Vorhersage von septischen Zuständen
ATE472611T1 (de) * 2005-11-25 2010-07-15 Trinity College Dublin Verfahren zur diagnose von sepsis durch analyse von cytokine mrna expression
EP2388594A1 (en) * 2010-05-17 2011-11-23 Roche Diagnostics GmbH GDF-15 based means and methods for survival and recovery prediction in acute inflammation
US20110312521A1 (en) * 2010-06-17 2011-12-22 Baylor Research Institute Genomic Transcriptional Analysis as a Tool for Identification of Pathogenic Diseases
US20120034214A1 (en) * 2010-07-22 2012-02-09 Isis Innovation Limited Methods and kits for determining the prognosis of pulmonary sarcoidosis
CN103403549B (zh) * 2011-01-11 2015-11-25 美迪恩斯生命科技株式会社 败血症的预后的预测方法
WO2013040099A2 (en) * 2011-09-12 2013-03-21 Langley Raymond Sepsis prognosis biomarkers
CN109451744B (zh) * 2016-06-26 2022-08-05 斯坦福大学托管董事会 用于危重患者的死亡预后的生物标志物

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1738908A (zh) * 2002-11-12 2006-02-22 贝克顿迪金森公司 使用生物标记谱诊断脓毒或者sirs
CN101208602A (zh) * 2005-04-15 2008-06-25 贝克顿迪金森公司 脓毒症的诊断
CN103492590A (zh) * 2011-02-22 2014-01-01 卡里斯生命科学卢森堡控股有限责任公司 循环生物标志物
CN105518153A (zh) * 2013-06-20 2016-04-20 因姆内克斯普雷斯私人有限公司 生物标志物鉴定
WO2015135071A1 (en) * 2014-03-14 2015-09-17 Hancock Robert E W Diagnostic for sepsis

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
An integrated transcriptome and expressed variant analysis of sepsis survival and death;Ephraim L Tsalik et al.;《Genome Medicine》;20141126;第6卷;第1-15页 *
Mortality prediction in sepsis via gene expression analysis: a community approach;Timothy E Sweeney et al.;《bioRxiv preprint》;20161219;第1-25页 *
Prospective validation of an 11‑gene mRNA host response score for mortality risk stratifcation in the intensive care unit;Andrew R. Moore et al.;《Scientifc Reports》;20210622;第11卷;第1-9页 *
脓毒症早期预警生物标志物的研究进展;许程 等;《检验医学》;20150531;第30卷(第5期);第533-536页 *

Also Published As

Publication number Publication date
CA3024724A1 (en) 2018-01-04
US20190106750A1 (en) 2019-04-11
US11608531B2 (en) 2023-03-21
US20190300959A1 (en) 2019-10-03
EP3475473A1 (en) 2019-05-01
US20180274031A1 (en) 2018-09-27
AU2022211785A1 (en) 2022-08-25
US10344332B2 (en) 2019-07-09
WO2018004806A1 (en) 2018-01-04
CN115161389A (zh) 2022-10-11
JP2022153436A (ja) 2022-10-12
US10648033B2 (en) 2020-05-12
CN109451744A (zh) 2019-03-08
JP2019530878A (ja) 2019-10-24
AU2017289600A1 (en) 2018-12-06
US20240011096A1 (en) 2024-01-11
EP3475473A4 (en) 2020-01-22

Similar Documents

Publication Publication Date Title
CN109451744B (zh) 用于危重患者的死亡预后的生物标志物
US20220127673A1 (en) Methods for diagnosis of bacterial and viral infections
US20230227911A1 (en) Methods for Diagnosis of Sepsis
EP3362579B1 (en) Methods for diagnosis of tuberculosis
WO2022235765A2 (en) Systems and methods for assessing a bacterial or viral status of a sample
WO2020096796A1 (en) Method for predicting severe dengue

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant